Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT02563808 |
Other study ID # |
817436 |
Secondary ID |
|
Status |
Completed |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
March 2013 |
Est. completion date |
February 2014 |
Study information
Verified date |
April 2023 |
Source |
University of Pennsylvania |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
The purpose of this study is to investigate the impact of incorporating "anticipated regret "
into standard patient decision aids. Participants in the Wharton Behavioral Lab will be
administered a standard patient decision aid and an "anticipated regret" augmented decision
aid. Participants will complete a computerized survey about their experiences with each
version, and their answers will be assessed for potential differences associated with the
incorporation of "Anticipated Regret."
Description:
Participants will be recruited through the Wharton Behavioral Lab. Upon arrival males will be
provided with two decision aids focusing on prostate cancer, while females will be provided
with two decision aids focusing on early breast cancer. One of these decision aids will be a
standard version, and one of these will be the anticipated regret-augmented version.
Participants will be randomized to which version they receive first to minimize the effect of
presentation order. After reviewing the materials, participants will immediately complete a
computerized survey at their work stations that will ask them to answer questions based on
the materials presented as well as how any hypothetical treatment decisions they would be
asked to make would have been influenced by them. Because these are healthy subjects
participating in a hypothetical decision-making process for sole purpose of research, the
intervention can neither be categorized as experimental or as the standard of care.